Compare BFC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | NBTX |
|---|---|---|
| Founded | 1894 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2018 | 2018 |
| Metric | BFC | NBTX |
|---|---|---|
| Price | $155.29 | $38.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $157.00 | $36.00 |
| AVG Volume (30 Days) | 82.1K | ★ 114.3K |
| Earning Date | 04-16-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 11.23 | N/A |
| EPS | ★ 1.78 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.67 | $58.17 |
| Revenue Next Year | $2.01 | N/A |
| P/E Ratio | $85.81 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $115.29 | $6.90 |
| 52 Week High | $154.42 | $57.14 |
| Indicator | BFC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 51.61 |
| Support Level | $134.81 | $38.89 |
| Resistance Level | N/A | $42.40 |
| Average True Range (ATR) | 4.97 | 2.45 |
| MACD | 0.53 | -0.05 |
| Stochastic Oscillator | 91.09 | 60.57 |
Bank First Corp is a United States-based company engaged in providing financial services, a full range of consumer and commercial financial institution services to individuals and businesses, including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.